Regulation of anti-tumorigenic pathways by the combinatory treatment of calcitriol and TGF-β in PC-3 and DU145 cells. Issue 209 (May 2021)

• Record Type: Journal Article
• Authors: García-Olivares, Mitzi; Romero-Córdoba, Sandra; Ortiz-Sánchez, Elizabeth; García-Becerra, Rocío; Segovia-Mendoza, Mariana; Rangel-Escareño, Claudia; Halhali, Ali; Larrea, Fernando; Barrera, David
• Is Part Of: Journal of steroid biochemistry and molecular biology. Issue 209(2021)
• Publication Date: 2021-05
• Subjects: Calcitriol -- TGF-β -- IGFBP3 -- CDKN1A -- CCNA1 -- CT45A2 -- UBE2D3 -- Prostate cancer cells -- Microarray; Steroid hormones -- Periodicals; Biochemistry -- Periodicals; Hormones -- Periodicals; Molecular Biology -- Periodicals; Hormones stéroïdes -- Périodiques; Steroid hormones; Periodicals; 572.579
• DOI: 10.1016/j.jsbmb.2021.105831
• Languages: English
• ISSNs: 0960-0760

Abstract

Highlights: Calcitriol with TGF-βs show higher inhibition of cell growth than each compound. Combinatory treatment impairs cell growth without affecting apoptosis. IGFBP3 and CDKNA1 were up regulated by combinatory treatment. Calcitriol with TGF-β1 reprogram prostate cancer signaling. RNA signatures confirm the regulation over cell proliferation and cell cycle. Abstract: Calcitriol and transforming growth factors beta (TGF-β) are involved in several biological pathways such as cell proliferation, differentiation, migration and invasion. Their cellular effects could be similar or opposite depending on the genetic target, cell type and context. Despite the reported association of calcitriol deficiency and disruption of the TGF-β pathway in prostate cancer and the well-known independent effects of calcitriol and TGF-βs on cancer cells, there is limited information regarding the cellular effects of calcitriol and TGF-β in combination. In this study, we in vitro analyze the combinatory effects of calcitriol and TGF-β on cell growth and apoptosis using PC-3 and DU145 human prostate cancer cell lines. Using high-throughput microarray profiling of PC-3 cells upon independent and combinatory treatments, we identified distinct transcriptional landscapes of each intervention, with a higher effect established by the combinatorial treatment, following by TGF-β1 and later by calcitriol. A set of genes and enriched pathways converge among the treatments, mainly between the combinatory scheme and TGF-β1, but the majority were treatment-specific. Of note, CYP24A1, IGFBP3, CDKN1A, NOX4 and UBE2D3 were significantly up-regulated upon the combinatorial treatment whereas CCNA1, members of the CT45A and APOBEC3 family were down-regulated. By public RNA signatures, we were able to confirm the regulation by the co-treatment over cell proliferation and cell cycle. We finally investigated the possible clinical impact of genes modulated by the combinatorial treatment using benchmark prostate cancer data. This comprehensive analysis reveals that the combinatory treatment impairs cell growth without affecting apoptosis and their combinatory actions might synergize and improved their individual effects to reprogram prostate cancer signaling.